Abstract
The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Current Pharmaceutical Design
Title: New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Volume: 18 Issue: 5
Author(s): Valerie Waters
Affiliation:
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Abstract: The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Export Options
About this article
Cite this article as:
Waters Valerie, New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas, Current Pharmaceutical Design 2012; 18 (5) . https://dx.doi.org/10.2174/138161212799315939
DOI https://dx.doi.org/10.2174/138161212799315939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-Level Aminoglycoside Resistance in Enterococcus Faecalis and Enterococcus Faecium; as a Serious Threat in Hospitals
Infectious Disorders - Drug Targets Potential Application of Antimicrobial Peptides in the Treatment of Bacterial Biofilm Infections
Current Pharmaceutical Design Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Macrolides Allergy
Current Pharmaceutical Design Protein Preparation, Crystallization and Preliminary X-Ray Crystallographic Analysis of N-Acetylglutamate Kinase from Streptococcus mutans
Protein & Peptide Letters Molecular Imaging of Vascular Thrombosis
Current Molecular Imaging (Discontinued) The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews TargetingQuorum Sensing and Competence Stimulation for Antimicrobial Chemotherapy
Current Drug Targets Prosthetic Devices with Nanostructurated Surfaces for Increased Resistance to Microbial Colonization
Current Pharmaceutical Biotechnology Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs
Current Topics in Medicinal Chemistry Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Novel Strategies for Combating Pathogenic Biofilms Using Plant Products and Microbial Antibiosis
Current Pharmaceutical Biotechnology Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets